VIKAS KUNDRA to Bevacizumab
This is a "connection" page, showing publications VIKAS KUNDRA has written about Bevacizumab.
Connection Strength
0.438
-
Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One. 2015; 10(6):e0131095.
Score: 0.400
-
CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.
Score: 0.038